Section Arrow
CBIO.NASDAQ
- Crescent Biopharma Inc
Quotes are at least 15-min delayed:2026/04/16 13:18 EDT
Regular Hours
Last
 19.62
-0.33 (-1.65%)
Day High 
19.885 
Prev. Close
19.95 
1-M High
20.68 
Volume 
33.96K 
Bid
19.47
Ask
19.8
Day Low
19.0501 
Open
19.77 
1-M Low
9.9 
Market Cap 
607.41M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 19.04 
20-SMA 15.96 
50-SMA 12.93 
52-W High 28.77 
52-W Low 8.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.81/-3.14
Enterprise Value
608.62M
Balance Sheet
Book Value Per Share
6.54
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
10.84M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.5833+0.0393+7.22%-- 
PBMPsyence Biomedical Ltd.6.66+3.78+131.25%-- 
ALLOAllogene Therapeutics2.325+0.155+7.14%-- 
ATAIAtaiBeckley Inc4.035+0.035+0.88%-- 
ACHVAchieve Life Sciences4.7811+1.2311+34.68%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.